Kigali, Rwanda and San Francisco, USA – 04 February 2026 — On World Cancer Day, the global community unites around a shared goal: reducing the burden of cancer. For Africa, that goal carries particular urgency.

Cancer outcomes on the continent are shaped not only by late diagnosis, but by unequal access to advanced therapies. While biologics and immunotherapies are redefining cancer care globally, too many African patients still face delays, shortages, and unaffordable prices for these life-saving medicines.

At Bio Usawa, we believe that closing this gap requires building durable, African-led solutions from local biomanufacturing to strong, trusted regulatory systems that ensure quality, safety, and scale. Access must not be a privilege, it is the foundation of equitable care.

“When cancer patients cannot access proven therapies, the issue is not innovation — it is infrastructure,” said Eric Karikari-Boateng, Bio Usawa’s Head of Global Regulatory Strategy. “Strengthening regulation and local production is how we turn equity from principle into practice.”

By establishing African-based biomanufacturing for high-quality monoclonal antibodies, we are working to shorten supply chains, reduce costs, and build resilient systems that serve patients first. Local production is not simply an industrial ambition — it is a public health imperative.

This World Cancer Day 2026, we reaffirm our commitment to a future where geography does not determine survival, and where African innovation helps deliver world-class cancer care for Africa and other underserved regions.

About Bio Usawa Inc.

Bio Usawa is Africa’s pioneering biotechnology company dedicated to democratizing access to life-saving biotherapeutics. Headquartered in Kigali, Rwanda, the company develops, licenses, and manufactures affordable monoclonal antibodies and biosimilars targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions.

                Eric Karikari-Boateng, Head of Global Regulatory Strategy at Bio Usawa.